Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Evolution; International Journal of Organic Evolution|June 24, 2016
Cryptic individual scaling relationships and the evolution of morphological scalingAustin P Dreyer, Omid Saleh Ziabari, Eli M Swanson, et al.Fertility and Sterility|September 11, 2024
Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related painFelipe Arbelaez, Hee-Koung Joeng, Azher Hussain, et al.Journal of Pharmacokinetics and Pharmacodynamics|April 26, 2019
Operating characteristics of stepwise covariate selection in pharmacometric modelingMalidi Ahamadi, Anna Largajolli, Paul M Diderichsen, et al.Clinical Pharmacology and Therapeutics|April 5, 2023
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical OutcomesAkshita Chawla, Ruthie Birger, Hong Wan, et al.CPT: Pharmacometrics & Systems Pharmacology|May 6, 2023
Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixantAkshita Chawla, Anna Largajolli, Azher Hussain, et al.Ebiomedicine|October 1, 2022
Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approachBhargava Kandala, Nele Plock, Akshita Chawla, et al.Clinical and Translational Science|March 26, 2025
Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19Akshita Chawla, Ruthie Birger, Brian M Maas, et al.Clinical Trials (London, England)|March 3, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.CPT: Pharmacometrics & Systems Pharmacology|October 6, 2023
Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individualsSébastien Bihorel, Youfang Cao, Akshita Chawla, et al.Pageof 1